{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Niacin", "query": { "intervention": "Placebo Niacin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 190, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Niacin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-15T08:13:12.193Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00105443", "title": "A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 602, "start_date": "2005-03", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2014-10-31", "last_synced_at": "2026-09-15T08:13:12.193Z", "location_count": 35, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00105443" }, { "nct_id": "NCT00901901", "title": "Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006)", "type": "DRUG" }, { "name": "Erlotinib (Tarceva)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 732, "start_date": "2009-05-21", "completion_date": "2018-05-23", "has_results": true, "last_update_posted_date": "2019-05-30", "last_synced_at": "2026-09-15T08:13:12.193Z", "location_count": 23, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Gainesville, Florida + 19 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00901901" }, { "nct_id": "NCT00110019", "title": "Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mucosal Melanoma", "Recurrent Melanoma", "Stage IIIA Skin Melanoma", "Stage IIIB Skin Melanoma", "Stage IIIC Skin Melanoma", "Stage IV Skin Melanoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Sorafenib Tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 823, "start_date": "2005-06", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2015-10-19", "last_synced_at": "2026-09-15T08:13:12.193Z", "location_count": 218, "location_summary": "Birmingham, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 175 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Burbank", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110019" }, { "nct_id": "NCT01004978", "title": "Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma", "Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Doxorubicin-Eluting Beads", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mitomycin", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Sorafenib Tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2009-10-28", "completion_date": "2022-12-21", "has_results": true, "last_update_posted_date": "2024-01-03", "last_synced_at": "2026-09-15T08:13:12.193Z", "location_count": 281, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 183 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01004978" }, { "nct_id": "NCT02558595", "title": "Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Polycystic Kidney Disease" ], "interventions": [ { "name": "Niacinamide", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 36, "start_date": "2015-09-22", "completion_date": "2017-12-18", "has_results": false, "last_update_posted_date": "2019-02-11", "last_synced_at": "2026-09-15T08:13:12.193Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02558595" }, { "nct_id": "NCT03685253", "title": "Nicotinamide Riboside for Diabetic Neuropathy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diabetic Neuropathy Peripheral" ], "interventions": [ { "name": "Niagen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "30 Years to 80 Years" }, "enrollment_count": 10, "start_date": "2019-01-24", "completion_date": "2022-05-01", "has_results": false, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-09-15T08:13:12.193Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03685253" }, { "nct_id": "NCT03821623", "title": "Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertension", "Aging" ], "interventions": [ { "name": "Nicotinamide riboside", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Douglas Seals", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 118, "start_date": "2019-05-10", "completion_date": "2025-06-01", "has_results": false, "last_update_posted_date": "2025-02-21", "last_synced_at": "2026-09-15T08:13:12.193Z", "location_count": 1, "location_summary": "Boulder, Colorado", "locations": [ { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03821623" }, { "nct_id": "NCT06200155", "title": "Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Depression, Anxiety", "Psilocybin-Assisted Psychotherapy", "Advanced Cancer" ], "interventions": [ { "name": "Psilocybin", "type": "DRUG" }, { "name": "Niacin", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": null, "sex": "ALL", "summary": "25 Years and older" }, "enrollment_count": 48, "start_date": "2024-04-16", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-09-15T08:13:12.193Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06200155" }, { "nct_id": "NCT06032923", "title": "Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus (Sle)" ], "interventions": [ { "name": "Nicotinamide Riboside", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 78, "start_date": "2024-03-13", "completion_date": "2028-08-01", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-15T08:13:12.193Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06032923" }, { "nct_id": "NCT07563322", "title": "Mechanistic Study of Nicotinamide Riboside on NAD+ Biology in Individuals With Combined Pulmonary Hypertension", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pulmonary Hypertension" ], "interventions": [ { "name": "Nicotinamide Riboside (NR)", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 10, "start_date": "2026-04-09", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-09-15T08:13:12.193Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07563322" } ] }